EIF2AK3 and medulloblastoma: Thus, using the VEGFR2 inhibitor SU5416 and the NAB to block VEGF-A/VEGFR2 signaling, our results suggest that moderate PERK activation promotes medulloblastoma cell migration and invasion through activation of VEGF-A/VEGFR2 signaling.